Literature DB >> 35958454

Serum sphingosine-1 phosphate level is increased in patients with hepatitis B and displays a positive association with liver fibrosis.

Mei Sun1, Ling Zeng1, Min Hu1.   

Abstract

OBJECTIVE: To investigate the difference in serum sphingosine-1 phosphate (S1P) concentration between the HBV hepatitis patients and healthy controls, and its relevant association with serum liver fibrosis indicators.
METHODS: A total of 28 HBsAg (+) HBeAg (+) Anti-HBc (+) hepatitis B patients, 42 HBsAg (+) Anti-HBe (+) Anti-HBc (+) hepatitis B patients, and 21 healthy subjects with normal liver function were included. Liquid chromatography-tandem mass method was used to detect the level of serum S1P.
RESULTS: SerumS1P concentration of Anti-HBe (+) hepatitis B patients was higher than that of the control group (P=0.017) and HBeAg (+) patients (P=0.007). At the same time, there was no significant difference in the serum S1P concentration between HBeAg (+) hepatitis B patients and the control group (P>0.05). Moreover, serum S1P concentration was positively correlated with liver fibrosis indices, Collage Type IV Protein (r=0.264; P=0.011), and Chitosanase 3-like protein 1 (r=0.295; P=0.004).
CONCLUSIONS: Serum S1P level is increased in patients with hepatitis B and displays a positive association with liver fibrosis. AJTR
Copyright © 2022.

Entities:  

Keywords:  Hepatitis B; chitosanase 3-like protein 1; collagen type IV protein; hepatic fibrosis; sphingosine 1-phosphate

Year:  2022        PMID: 35958454      PMCID: PMC9360858     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  47 in total

1.  Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Oscar Mammoliti; Adeline Palisse; Caroline Joannesse; Sandy El Bkassiny; Brigitte Allart; Alex Jaunet; Christel Menet; Beatrice Coornaert; Kathleen Sonck; Inge Duys; Philippe Clément-Lacroix; Line Oste; Monica Borgonovi; Emanuelle Wakselman; Thierry Christophe; Nicolas Houvenaghel; Mia Jans; Bertrand Heckmann; Laurent Sanière; Reginald Brys
Journal:  J Med Chem       Date:  2021-05-03       Impact factor: 7.446

2.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

Review 3.  Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

Authors:  Richard L Proia; Timothy Hla
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

Review 4.  Burden of liver diseases in the world.

Authors:  Sumeet K Asrani; Harshad Devarbhavi; John Eaton; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

5.  Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.

Authors:  Hironari Kawai; Yosuke Osawa; Michitaka Matsuda; Tomoyuki Tsunoda; Keisuke Yanagida; Daisuke Hishikawa; Miku Okawara; Yuzuru Sakamoto; Tomonari Shimagaki; Yuriko Tsutsui; Yuichi Yoshida; Shiori Yoshikawa; Kana Hashi; Hiroyoshi Doi; Taizo Mori; Taiji Yamazoe; Sachiyo Yoshio; Masaya Sugiyama; Daisuke Okuzaki; Haruki Komatsu; Ayano Inui; Miwa Tamura-Nakano; Chinatsu Oyama; Hideo Shindou; Hironori Kusano; Masayoshi Kage; Toru Ikegami; Katsuhiko Yanaga; Tatsuya Kanto
Journal:  Hepatology       Date:  2021-12-22       Impact factor: 17.298

Review 6.  Principles of bioactive lipid signalling: lessons from sphingolipids.

Authors:  Yusuf A Hannun; Lina M Obeid
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02       Impact factor: 94.444

7.  CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis.

Authors:  Haijun Huang; Tiangang Wu; Jian Mao; Yongxing Fang; Jiajie Zhang; Lihua Wu; Shu Zheng; Biaoyang Lin; Hongying Pan
Journal:  OMICS       Date:  2015-06

Review 8.  Sphingosine 1-phosphate: Lipid signaling in pathology and therapy.

Authors:  Andreane Cartier; Timothy Hla
Journal:  Science       Date:  2019-10-18       Impact factor: 47.728

9.  Non-invasive biomarkers of Fontan-associated liver disease.

Authors:  Juliet Emamaullee; Sara Khan; Carly Weaver; Cameron Goldbeck; George Yanni; Rohit Kohli; Yuri Genyk; Shengmei Zhou; Nick Shillingford; Patrick M Sullivan; Cheryl Takao; Jon Detterich; Paul F Kantor; John D Cleveland; Cynthia Herrington; S Ram Kumar; Vaughn Starnes; Sarah Badran; Neil D Patel
Journal:  JHEP Rep       Date:  2021-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.